News
CALC
5.60
-0.89%
-0.05
CALCIMEDICA ANNOUNCES UPCOMING PRESENTATION AT DIGESTIVE DISEASE WEEK 2024
Reuters · 4d ago
Weekly Report: what happened at CALC last week (0429-0503)?
Weekly Report · 5d ago
Weekly Report: what happened at CALC last week (0422-0426)?
Weekly Report · 04/29 11:04
Analysts Offer Insights on Healthcare Companies: CalciMedica (CALC), Acrivon Therapeutics, Inc. (ACRV) and Viking Therapeutics (VKTX)
TipRanks · 04/25 12:07
CalciMedica Announces Last Patient Enrolled In Phase 2b CARPO Trial Of Auxora In Acute Pancreatitis; Full Target Enrollment Of 216 Patients Achieved
Full target enrollment of 216 patients achieved in the CARPO trial of Auxora in acute pancreatitis. Topline data from CARPO expected in 2Q 2024. Auxora is a potent and selective small molecule inhibitor of Orai1-containing CRAC channels. The last patient has been enrolled in the Phase 2b CARPO study.
Benzinga · 04/24 12:08
CALCIMEDICA ANNOUNCES LAST PATIENT ENROLLED IN PHASE 2B CARPO TRIAL OF AUXORA™ IN ACUTE PANCREATITIS
Reuters · 04/24 12:00
CALCIMEDICA INC: TOPLINE DATA FROM CARPO EXPECTED IN 2Q 2024
Reuters · 04/24 12:00
Weekly Report: what happened at CALC last week (0415-0419)?
Weekly Report · 04/22 10:56
Weekly Report: what happened at CALC last week (0408-0412)?
Weekly Report · 04/15 10:48
Weekly Report: what happened at CALC last week (0401-0405)?
Weekly Report · 04/08 10:53
CalciMedica And 2 Other Penny Stocks Insiders Are Buying
When insiders purchase or sell shares, it indicates their confidence or concern around the company's prospects. The Dow Jones index closed lower by around 400 points on Tuesday. Recent notable insider transactions for penny stocks include RENN Fund, Inc. And Tecogen Inc. CalciMedica and RENN fund are among the companies with recent notable insider trades.
Benzinga · 04/03 13:13
CalciMedica Price Target Maintained With a $14.00/Share by Oppenheimer
Dow Jones · 04/01 13:26
Oppenheimer Maintains Outperform on CalciMedica, Maintains $14 Price Target
Benzinga · 04/01 13:16
Weekly Report: what happened at CALC last week (0325-0329)?
Weekly Report · 04/01 10:51
Analysts Offer Insights on Healthcare Companies: CalciMedica (CALC), Apollomics (APLM) and Iterum Therapeutics (ITRM)
TipRanks · 04/01 10:30
CalciMedica GAAP EPS of -$7.66 beats by $3.78
Earnings News CalciMedica GAAP EPS of -$7.66 beats by $3.78. As of December 31, 2023, Calci medica had $11.2 million in cash, cash equivalents and short-term investments. Calcimedica's FY GAAP earnings of $7.78 per share is better than expected.
Seeking Alpha · 03/28 17:40
CALC Stock Earnings: CalciMedica Reported Results for Q4 2023
CalciMedica reported earnings per share of -23 cents for the fourth quarter of 2023. The company did not report any revenue for the quarter. InvestorPlace Earnings is a project that automates coverage of quarterly earnings reports. CalciMedicanica just reported results for fourth quarter.
Investorplace · 03/28 15:53
CalciMedica Q4 EPS $(0.23)
Benzinga · 03/28 12:45
CalciMedica Inc reports results for the quarter ended in December - Earnings Summary
CalciMedica Inc reports results for the quarter ended in December. The company reported a quarterly adjusted loss of 23 cents per share. The mean expectation of four analysts was for a loss of 87 cents. The average analyst rating on the company's shares is "buy"
Reuters · 03/28 12:22
Press Release: CalciMedica Reports 2023 Financial -2-
CalciMedica is a clinical-stage biopharmaceutical company focused on developing novel CRAC channel inhibition therapies for inflammatory and immunologic diseases. The company's proprietary technology targets the inhibition of CRAC channels to modulate the immune response and protect against tissue cell injury. Its lead product candidate Auxora(TM) has demonstrated positive clinical results in multiple clinical trials.
Dow Jones · 03/28 11:00
More
Webull provides a variety of real-time CALC stock news. You can receive the latest news about CALCIMEDICA INC through multiple platforms. This information may help you make smarter investment decisions.
About CALC
CalciMedica, Inc. is a clinical-stage biopharmaceutical company focused on developing novel calcium release-activated calcium (CRAC) channel inhibition therapies for acute and chronic inflammatory and immunologic illnesses. The Company's technology targets the inhibition of CRAC channels to modulate the immune response and protect against tissue cell injury. Its lead product candidate is Auxora, a potent and selective intravenous (IV) formulated small molecule CRAC channel inhibitor containing the active compound zegocractin (formerly referred to as CM4620) that, in animal models, reduced acute epithelial and/or endothelial cell injury and inflammation in organs, such as the pancreas, lungs and kidneys. The Company is conducting a Phase 2b trial (called CARPO - NCT04681066) for acute pancreatitis (AP) with systemic inflammatory response syndrome (SIRS), as well as supporting the ongoing Phase 1/2 asparaginase induced pancreatic toxicity (AIPT) study (called CRSPA - NCT04195347).